Acadia (ACAD) Q2 Revenue Rises 9%
Acadia Pharmaceuticals (NASDAQ:ACAD), a neuroscience-focused biopharma company behind treatments for central nervous system diseases, reported its earnings for Q2 2025 on August 6, 2025. The most notable news was a slight beat on both GAAP earnings and revenue, driven by ongoing growth in its NUPLAZID and DAYBUE product lines. Earnings per share (GAAP) reached $0.16, ahead of the analyst expectation of $0.14 (GAAP), while revenue (GAAP) stood at $264.6 million, above the $262.0 million GAAP consensus. Compared to Q2 2024, revenue (GAAP) increased by 9.3%, though GAAP net income declined due to higher tax and selling expenses. The quarter demonstrated operational progress, steady product sales growth, and cautious optimism for the remainder of FY2025.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Acadia Pharmaceuticals develops medicines for central nervous system disorders, focusing mainly on neurological and rare diseases. Its primary commercial products are NUPLAZID, a treatment for hallucinations and delusions related to Parkinson’s disease psychosis, and DAYBUE, a therapy for Rett syndrome, a rare genetic neurological disorder.
Source Fool.com
